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Dietary fatty acid intake is associated with the risk of development
and progression of prostate, colon and breast cancer (Marnett,
1992; Rose, 1997). In vitro and in vivo studies suggest that the
availability of polyunsaturated fatty acids contributes to increased
cancer cell growth, and that inhibitors of the eicosanoids synthesis
pathway inhibit cell proliferation (Rose and Connolly, 1991;
Connolly et al, 1997).
Arachidonic acid (AA) is derived from the essential polyunsatu-
rated fatty acid, linoleic acid, which is commonly available in
dietary fat. It is the major precursor of biologically active
eicosanoids, which include prostaglandins, thromboxanes and
leukotrienes. Among these is prostaglandin E2 (PGE2), a product
catalysed by the key enzyme cyclo-oxygenase (COX, EC
1.14.99.1). Two isoforms of COX exist in human prostate cells.
COX-1 is a constitutively expressed exzyme, whereas COX-2 is
inducible. O’Neill and Ford-Hutchinson (1993) have reported that
the human prostate cells express similar amounts of COX-1 and
COX-2. In human prostate tissues, PGE2 is the only significant
eicosanoid produced (Chaudry et al, 1994). PGE2 induces a variety
of cell responses depending on the tissue type and the receptors
involved, such as immune regulation (Monick et al, 1987; Juzan et
al, 1992; Marnett, 1992), smooth muscle contraction (Coleman
and Kennedy, 1985) and regulation of water re-adsorption in
kidney (Smith, 1989). Previous studies with osteoblasts and
prostate cancer cells have demonstrated that PGE2 stimulates cell
growth (Raisz et al, 1993; Tjandrawinata et al, 1997).
Studies from this laboratory indicate that AA stimulates growth
of a prostate cell line, PC-3 (manuscript submitted). Because of
the role of PGE2 in prostate cancer cell growth, we hypothesized
that AA had the stimulatory effect on the prostate cancer cells
through the activity of its metabolite PGE2, and aimed to under-
stand the signal transduction events following AA administration
which lead to the growth of the cells. After being synthesized and
exported out of the cells, PGE2 exerts its functions by interacting
with the PGE2 receptors (EPs), which are 7-domain transmem-
brane cell surface receptors. Four subtypes of EP receptors have
been identified and characterized. These receptors are coupled to
G proteins, and activate or inhibit second messenger systems
inside the cell. EP1 causes influx of Ca2+ and activation of protein
kinase C (PKC); receptors EP2 and EP4 activate the adenylate
cyclase which increases cellular cyclic AMP level and activates
protein kinase A (PKA); EP3 signals primarily through an
inhibitory G protein to decrease intracellular cyclic AMP levels
(Negishi et al, 1995).
Despite the important association of AA and PGE2 with prostate
cancer, the signals mediating the biological functions of these
molecules in prostate cancer cells are not fully understood. The
signalling pathways mediating AA- or PGE2-induced cell growth
or expression of growth-related proto-oncogenes have been inves-
tigated in a number of studies with varying conclusions. In bone
cells, a PKA-mediated mechanism has been suggested (Fitzgerald
et al, 1999; Weinreb et al, 1999). A study of smooth muscle cells
demonstrated a role for PKC as a mediator of AA-induced c-fos
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however, there are conflicting data on whether PKC or PKA is
involved (Kacich et al, 1988; Mehmet et al, 1990; Danesch et al,
1994). Our results indicate that the PKA-dependent pathway via
the EP4 receptor is responsible for mediating AA-induced c-fos
expression in human prostate cancer cells.
MATERIALS AND METHODS
Materials
AA, flurbiprofen, and 12-O-tetradecanoylphorbol 13-acetate
(TPA) were purchased from Sigma (St Louis, MO, USA). PKC
inhibitor GF109203X and PKA inhibitor H-89 were from
BIOMOL (Plymouth Meeting, PA, USA). PGE2 was from Oxford
(Oxford, MI, USA). RPMI-1640 medium, L-glutamine, and anti-
biotics were from UCSF Cell Facility (San Francisco, CA, USA).
Fetal calf serum (FCS) was purchased from Hyclone Laboratories
(Logan, UT, USA).
Cell culture
The PC-3, DU145 and LNCaP human prostate cancer cell lines
were cultured in complete RPMI-1640 medium supplemented
with 10% FCS, 2 mML -glutamine, 25 mM glucose, 1 mM pyruvic
acid, 100 units ml–1 penicillin, 100 mg ml–1 streptomycin and
0.25 mg ml–1 amphotericin B. The PrEC normal human prostate
epithelial cells (Clonetics, San Diego, CA, USA) were maintained
in the PrEGM medium (Clonetics). All cells were cultured with
5% carbon dioxide at 37°C. For c-fos expression experiments,
cells were grown in complete RPMI medium with 5% FCS for 2
days, and then 1% FCS for 24 h before cells were harvested for
RNA isolation.
PCR primers
Specific polymerase chain reaction (PCR) primers (see Table 1)
were designed by MHF. The primer pairs span introns of the genes,
so that the reverse transcription PCR (RT-PCR) products may be
distinguished from any possible PCR products resulted from cont-
aminating genomic DNA. Primers were synthesized by Operon
Technologies (Alameda, CA, USA).
Semi-quantitative RT-PCR
Semi-quantitative kinetic RT-PCR was used for analysis since this is
the most versatile and inexpensive method available. The PCR effi-
ciency of the reactions was checked by examining the slopes of the
PCR product curves and internal standards of housekeeping genes
from the same samples. RNA was isolated from cells grown in 6-
well plates using the TriReagent (Sigma) as recommended by the
company. RNA was quantified in the GeneQuant spectro-
photometer (Pharmacia, Piscataway, NJ, USA). The RNA PCR kit
from PE Applied Biosystems (Foster City, CA, USA) was used for
reverse transcription and PCR following procedures recommended
by the manufacturer. An aliquot of 1.5 mg RNA was reverse tran-
scribed in 30 ml of buffer. Five microlitres of the reverse transcrip-
tion reaction was PCR-amplified using specific primers. A
temperature cycle in PCR was 94°C for 1 min 40 s, 63°C for 1 min
10 s and 72°C for 1 min 40 s. PCR was carried out in a Robocycler
40 (Stratagene, San Diego, CA, USA) for various cycle numbers
depending on the primers used (the cycle numbers are described
in the legends for Tables and Figures). PCR cycle numbers were
maintained within a linear amplification range. The PCR products
were separated by electrophoresis in 2% agarose gels. The gels were
photographed and DNA bands of interest were scanned at 400 dpi
with an Epson Perfection 636 scanner. Areas and densities of the
DNA bands were determined using the SigmaGel software (Sigma).
PGE2 assay
An aliquot of culture medium was collected and frozen at –70°C
before the cells were harvested for RNA isolation. PGE2 levels in
the culture medium samples were determined using a PGE2 mono-
clonal enzyme immunoassay kit (Cayman Chemical, Ann Arbor,
MI, USA), following the protocols recommended by the company.
A Dynatech MR5000 microplate reader (Dynatech Laboratories,
Chantilly, VA, USA) was used to read the assay results. Data were
analysed using the BioLinx 2.0 software (Dynatech).
Statistical analysis
For each treatment in the experiments, three independent samples
were seeded, treated and their RNA or media samples analysed
separately. Mean and standard deviation (s.d.) of the three samples
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Table 1 Primers used in RT-PCR
Gene Orientation Sequence Product size (bp)
c-fos Sense 5¢ GAATAAGATGGCTGCAGCCAAATGCCGCAA 236
Anti-sense 5¢ CAGTCAGATCAAGGGAAGCCACAGACATCT
Cyclophilin Sense 5¢ CGTCTCCTTTGAGCTGTTTGCAGAC 628
Anti-Sense 5¢ CATAATCATAAACTTAACTCTGCAATCCAGC
EP1 Sense 5¢ CCACCACCTTCCTGCTGTTCG 1037
Anti-sense 5¢ GGTGGGCTGGCTTAGTCGTTG
EP2 Sense 5¢ CCTGTTGGGCACTTTGTTGGT 784
Anti-sense 5¢ GGGGTCTAGGATGGGGTTCAC
EP3 Sense 5¢ CGCCTCAACCACTCCTACACA 837
Anti-sense 5¢ GCAGACCGACAGCACGCACAT
EP4 Sense 5¢ AGGATTGCTTCTGTGAACCCCAT 344
Anti-sense 5¢ GAGGTGGTGTCTGCTTGGGTCAG2002 Y Chen and M Hughes-Fulford
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are shown in the figures. One-way analysis of variance (ANOVA)
was performed using the SigmaStat (Sigma) software to obtain the
P-values for comparison between treatments.
RESULTS
AA transiently increases c-fos mRNA expression in
PC-3 cells
A previous study from this laboratory demonstrated that AA
induces  c-fos expression in the PC-3 human prostate cancer cells
(manuscript submitted). In this study, AA was added to the PC-3
cells at a concentration of 1 mg ml–1 since previous work demon-
strated that c-fos expression can be up-regulated with as low as
0.1 mg ml–1 of AA, and that the effect is near maximum when the
AA concentration is at 0.5 mg ml–1. Fifteen, 30, 60 and 180 min
after addition of AA, total RNA was isolated from the cells and
was subjected to RT-PCR analysis to observe level of c-fos
mRNA. Table 2 summarizes the relative level of c-fos product
after being normalized to the internal control, cyclophilin. c-fos
message was induced as early as 15 min after AA addition to cell
culture, and was greater than 1.9-fold higher than the non-treated
control at 1 h. Three hours after AA addition, c-fos mRNA level
began to decrease, suggesting that c-fos induction was transient
and was regulated by other downstream events. Based on these
observations, cells and medium samples were collected 1 h after
AA was added to culture media for all subsequent AA-induction
experiments.
AA-induced c-fos expression is mediated by PGE2
Because AA is the precursor of PGE2, it was speculated that the
AA-induced c-fos expression was due to increased PGE2 produc-
tion by the PC-3 cells. Culture medium samples collected from the
experiment presented in Table 2 were analysed for their PGE2
levels. As expected, PGE2 production of the PC-3 cells increased
shortly after its precursor, AA, became available to the cells and
PGE2 level remained elevated for at least 3 h (Table 2).
In order to confirm that PGE2 mediated AA-induced c-fos
expression, we blocked PGE2 synthesis with a non-steroidal
anti-inflammatory drug (NSAID). Flurbiprofen, which suppresses
cyclo-oxygenases and subsequently PGE2 production, was added
to the cells before the AA treatment. As shown in Figure 1A,
c-fos message induction by AA was inhibited by flurbiprofen,
suggesting an important role for PGE2 production in this event.
Increased c-fos expression in PC-3 cells was similarly achieved by
PGE2 treatment (Figure 1B). The effect of flurbiprofen on PGE2
production by PC-3 cells was measured. PGE2 level of the culture
media was increased more than sevenfold by AA, but this increase
was abolished by flurbiprofen treatment (Figure 2). These data
strongly suggest that AA increases c-fos expression via a PGE2
mechanism.
AA-induced c-fos expression is dependent on the PKA
signalling pathway
The EP receptors for PGE2 are coupled to either PKC or PKA
pathways. To determine which EP receptor signalling pathway is
Table 2 AA-induced c-fos mRNA expression and PGE2 production in PC-3
cells
Incubation time with AA Relative c-fos PGE2 concentration 
product (pg ml–1)
Control 2.81 ± 0.26 80 ± 34
15 min 3.59 ± 1.09 361 ± 107
30 min 4.42 ± 0.47 402 ± 18
1 h 5.46 ± 0.53 425 ± 52
3 h 3.62 ± 0.69 558 ± 131
Total RNA was isolated from the PC-3 cells after incubation with AA
(1 mg ml–1) for a time period indicated in the Table. RT-PCR with c-fos and
cyclophilin primers was performed on the RNA samples. PCR reactions with
c-fos and cyclophilin primers had 29 and 19 temperature cycles respectively.
The amount of c-fos RT-PCR product was normalized to that of the
cyclophilin product. Culture medium samples from the same experiment was
assayed for PGE2 level. The numbers represent mean ± s.d. of three
independent samples.
3
2
 1
0
5
4
3
2
 1
0
Ctrl
Ctrl PGE2
AA Flub Flub+AA
R
e
l
a
t
i
v
e
 
c
-
f
o
s
 
R
T
-
P
C
R
 
p
r
o
d
u
c
t
R
e
l
a
t
i
v
e
 
c
-
f
o
s
 
R
T
-
P
C
R
 
p
r
o
d
u
c
t
A
B
Figure 1 Effect of NSAID and PGE2 on AA-induced c-fos expression in
PC-3 cells. Cells were treated as indicated before harvested for total RNA
isolation and subsequent RT-PCR. Amount of c-fos RT-PCR product was
normalized to that of cyclophilin product. Mean ± s.d. of three independent
samples is shown in this bar graph. Ctrl = control; Flub = flurbiprofen.
(A) Flurbiprofen (30 mM) was added to the cells 3 h before harvest and AA
(1 m ml–1) was added 1 h before harvest. c-fos induction by AA was
statistically significant (P = 0.004) in absence of flurbiprofen, but was not
significant (P = 0.840) in presence of flurbiprofen. (B) PGE2 (4 mg ml–1) was
added to the cells 30 min before harvest. Induction by PGE2 was significant
(P = 0.009)involved in the AA-induced c-fos expression in the PC-3 cells,
specific protein kinase inhibitors were used to treat the cells before
AA was added. Treatment with H-89, a selective inhibitor of PKA
(Chijiwa et al, 1990), resulted in loss of c-fos induction by AA
(Figure 3). Inhibition of PKA also lowered PGE2 production by
2.8-fold after AA was added to the cells (Figure 4). This reduced
PGE2 and PKA mediate c-fos induction by AA 2003
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Figure 2 NSAID inhibits PGE2 production. Culture medium samples were
collected prior to RNA isolation for the experiment described in Figure 1.
Each bar represents the mean ± s.d. of three independent samples.
Differences in PGE2 levels were not significant except for the treatment with
AA alone (P < 0.001)
Figure 5 PKC inhibitor has no effect on AA-induced c-fos expression. The
PKC specific inhibitor, GF109203X, was added to the cells at 500 nM 30 min
before addition of AA (1 mg ml–1). TPA (1.6 mM) was added 30 min before cells
were harvested for RNA isolation. AA was added 1 h before harvest. Amount
of c-fos RT-PCR product was normalized to the cyclophilin product, and
expressed as mean ± s.d. (A) Effect of GF109203X on AA-induced c-fos
expression. Induction by AA was significant in presence of GF109203X
(P = 0.007). (B) GF109203X inhibits TPA-induced c-fos expression
Figure 6 PKC inhibitor does not affect PGE2 production from AA. Culture
medium samples collected from the experiment described in Figure 5A were
assayed for PGE2 levels. Each bar represents mean ± s.d. of three
independent samples. Increase of PGE2 production by AA was significant in
absence (P < 0.001) or presence (P = 0.002) of GF109203X
Figure 3 PKA inhibitor inhibits AA-induced c-fos expression. The PKA
specific inhibitor, H-89, was added to the cells at 30 mM 1 h before addition of
AA. RNA was isolated from the cells 1 hour after addition of AA (1 mg ml–1).
Amount of c-fos RT-PCR product was normalized to the internal control,
cyclophilin, and expressed as mean ± s.d. c-fos induction by AA was
significant (P < 0.001) without H-89, but was not significant (P = 0.713) in
presence of H-89
Figure 4 Effect of H-89 on PGE2 production from AA. Culture medium
samples collected from the experiment described in Figure 3 were assayed
for PGE2 levels. Each bar represents mean ± s.d. of three independent
samples. Increase of PGE2 production by AA was significant in absence
(P < 0.001) or presence (P = 0.002) of H-89PGE2 level, however, was still 4.6-fold higher than the control
samples, or 3.7-fold higher than the samples treated with H-89 but
not with AA.
The specific PKC inhibitor, GF109203X (Toullec et al, 1991),
was added to the cells prior to AA treatment in order to determine
whether PKC is involved in c-fos induction in PC-3 cells. Figure
5A shows that inhibition of PKC did not significantly block AA-
induced c-fos expression. The inhibitory effect of GF109203X was
demonstrated by its strong inhibition of c-fos expression induced
by TPA, which is a potent activator of PKC (Figure 5B). AA-
induced PGE2 production in PC-3 cells was also not affected by
treatment with GF109203X (Figure 6).
Taken together, the results suggest that the PKA but not PKC
signalling pathway is responsible for PGE2 signal transduction that
leads to increased c-fos expression after addition of AA.
Therefore, the EP1 receptor, which activates the PKC pathway, is
not likely to be involved in receiving the PGE2 signal in PC-3
cells.
Human prostate cells express the prostaglandin
receptors EP4 and EP2
Expression of different EP receptors was examined in three human
prostate cancer cell lines (PC-3, LNCaP, and DU145) and in PrEC
normal prostate cells. Cells were grown in their normal growth
media before harvested for RNA isolation and RT-PCR. A strong
band was detected when the RT samples were PCR-amplified with
EP4 primers after 31 cycles. This band was present in all four cell
lines examined. Using the EP2 primers, only a weak band was
present in all the cells after 40 cycles of amplification, suggesting
a very low copy number. No RT-PCR product of the expected size
was detected in any of the cell lines when EP1 or EP3 primers
were used (Figure 7), even after varying the magnesium concen-
trations in PCR (data not shown). We conclude that the human
prostate cells express EP4 and EP2 receptors and probably not
EP1 or EP3.
DISCUSSION
The current study suggests that the mechanism by which AA
increases c-fos expression and growth in PC-3 cells involves
production of PGE2 from AA, binding of PGE2 to the EP4 and/or
EP2 receptors, and subsequent activation of the PKA pathway
which eventually leads to expression of growth-related genes
(Figure 8). Under normal physiological conditions, AA is released
from membrane phospholipids by phospholipases upon stimula-
tion to synthesize eicosanoids (Smith, 1989). Because human cells
can not synthesize AA de novo, AA has to be obtained directly
from the diet, or synthesized from linoleic acid, which is also an
essential fatty acid. AA is then present in serum either as an
albumin-bound acid, or as part of lipids present in lipoproteins.
Habenicht et al (1990) have demonstrated that cholesteryl-AA is
taken up by the cells via the LDL receptor pathway. Serum
albumin-bound AA enters the cells by endocytosis (Geuskens et
al, 1994; Iturralde et al, 1991; Uriel et al, 1994). After transporta-
tion into the cells, AA is incorporated into the lipid pool as part of
phospholipids (Chilton et al, 1996). The mechanisms by which
prostaglandins (synthesized from AA via the cyclo-oxygenase
pathway) facilitate cancer transformation include generation of
mutagens, stimulation of cell growth, tumour promotion and
immune suppression (Marnett, 1992). The importance of the
cyclo-oxygenase products in prostate cancer has also been demon-
strated by a recent study (Liu et al, 1998) in which a specific COX-
2 inhibitor induced apoptosis of the LNCaP human prostate cell
line.
c-fos is one of the earliest induced growth response genes (Lau
and Nathans, 1987; Angel and Karin, 1991). In this study, expres-
sion of c-fos measured by semi-quantitative RT-PCR increased
> 1.9-fold when prostate cancer cells were treated with AA in all
experiments. The increased expression of c-fos may, at least in
part, account for the increased PC-3 cell growth as previously
observed (Tjandrawinata et al, 1997). Our results strongly suggest
that AA induces c-fos expression through the biological activity of
2004 Y Chen and M Hughes-Fulford
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Figure 7 EP receptor expression in human prostate cell lines. Total RNA
from the PC-3, DU145, LNCaP and PrEC cells grown in their regular growth
media were subjected to RT-PCR using specific EP primers. The PCR
products were separated on agarose gels, and the portions of the gel
corresponding to the expected DNA size of the PCR products are shown in
the middle of the figure. The bands in the 100 bp ladder immediately below
the expected PCR products are indicated by the arrows at left. The
cyclophilin (CPHI) product is included in this figure as an internal control.
PCR cycle numbers for the different primer pairs are: cyclophilin – 20 cycles;
EP4 – 31 cycles; EP1, EP2, and EP3 – 40 cycles
Figure 8 Mechanism involved in increased c-fos expression by AA in PC-3
cells. AA is transported inside the cell and catalysed by the COX enzymes
into PGE2. PGE2 is then secreted from the cells and binds to the EP4 and/or
EP2 receptors. The EP4 or EP2 receptors activate the PKA pathway which
sends signals inside the nucleus to induce c-fos gene transcription. Inhibition
of the COX enzymes with NSAID (e.g. flurbiprofen) or inhibition of PKA with
H-89 interrupts the signals from AA to c-fos inductionPGE2 and PKA mediate c-fos induction by AA 2005
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its product PGE2 for two reasons. First, PGE2 had a similar effect
on c-fos expression in PC-3 cells; and second, treatment with a
cyclo-oxygenase inhibitor suppressed the induction of c-fos
expression by AA. To understand the signal transduction
pathway(s) involved in AA-induced c-fos expression in the
prostate cancer cells, specific protein kinase inhibitors were used.
The results clearly indicate a role of PKA, but not PKC, in
the activation of the signal transduction event. Therefore, the
prostaglandin receptor(s) that mediate this event must be EP2
and/or EP4, which are linked to the PKA pathway. Consistent with
the results from protein kinase inhibition experiments, RT-PCR
detected EP4 as the major EP receptor expressed in human
prostate cells, with a small amount of EP2 expression also
detected. Expression of EP1 and EP3 was not detected. Expression
of specific types of EP receptors appears to be the mechanism used
by different cell types for carrying out various physiological func-
tions of the eicosanoids.
Interestingly, the PKA inhibitor H-89 partially inhibited PGE2
production from AA. This, however, was unlikely the cause for the
complete loss of AA-induction of c-fos expression, because the
PGE2 level in presence of H-89 and AA was still much higher than
in control samples. Two possibilities are proposed to explain
this partial inhibition of PGE2 synthesis. First, COX-2 is a feed-
forward enzyme up-regulated by its product PGE2 (Pilbeam et al,
1995; Tjandrawinata et al, 1997). Inhibition of PKA blocks the
pathway by which PGE2 exerts its cellular functions through the
EP4/2 receptors in PC-3 cells. This presumably prevents further
activation of cyclo-oxygenases, thus decreasing the amount of
subsequent PGE2 production. Second, it is possible that other stim-
ulating factors are needed for conversion of AA into PGE2, and the
PKA inhibitor partially blocked the transmission of such signals.
In our study, we also demonstrated c-fos inducibility by the
phorbol ester TPA, which is a potent PKC activator and mitogen.
The fact that activation of PKC in absence of the EP1 receptor
induced c-fos further supported the role of EP receptors as the
decisive control for the different responses to eicosanoids.
The c-fos promoter contains a serum response element (SRE),
which is activated by signals through the PKC pathway (Buscher
et al, 1988; Gilman, 1988). A cyclic AMP response element (CRE)
is also located at 264/257 of the c-fos promoter. In mouse
osteoblasts which also depend on the PKA pathway for PGE2-
induced  c-fos expression, the CRE but not the SRE has been
suggested to provide the inducibility by PGE2 (Fitzgerald et al,
1999). In that study the c-fos promoter with 5¢ deletions was fused
to a reporter gene and the effect of exogenous PGE2 on promoter
activity studied. With the findings presented here, the CRE is also
expected to confer PGE2-inducibility in the PC-3 cells.
This report has elucidated several key steps by which certain
dietary fatty acids, such as AA and its precursors, increase human
prostate cell growth and cancer risk. Our results strongly suggest
that PGE2, the EP4/2 receptors, and the PKA pathway are media-
tors of AA induced c-fos expression in the human prostate cancer
cell line PC-3.
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